BeOne Medicines swung into the black with a net profit of CNY1.6 billion (USD235 million) in the first quarter from a year earlier, driven by improved operational efficiency, the Chinese biotech firm said. Revenue surged 31% to CNY10.5 billion (USD1.6 billion).